Corient Private Wealth
ANIK icon

Corient Private Wealth’s Anika Therapeutics ANIK Stock Holding History

Corient Private Wealth’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$518K Buy
35,415
+2,192
+7% +$32.5K ﹤0.01% 2197
2026
Q1 		$482K Buy
33,223
+999
+3% +$11.6K ﹤0.01% 2050
2025
Q4 		$310K Buy
32,224
+1,324
+4% +$12.7K ﹤0.01% 2151
2025
Q3 		$290K Buy
+30,900
New +$295K ﹤0.01% 2137

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Corient Private Wealth's ANIK Position: Q2 2026 in Review

Corient Private Wealth increased its Anika Therapeutics (ANIK) stake by 6.6% in Q2 2026, buying an estimated $32.5K and bringing the position to 35,415 shares worth $518K. The position accounts for ﹤0.01% of the portfolio, ranked #2197.

Corient Private Wealth first reported a position in ANIK in Q3 2025 and has held it in 4 quarters since. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Corient Private Wealth held 35,415 shares of Anika Therapeutics worth $518K as of Q2 2026.
  • Corient Private Wealth bought 2,192 Anika Therapeutics shares in Q2 2026, an estimated $32.5K.
  • Anika Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2197 holding.
  • Corient Private Wealth first reported a position in Anika Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.